Semaglutide for PCOS: what we know, what's still uncertain, and who to ask

Step 1: understand why weight and PCOS are so closely connected

Polycystic ovary syndrome affects an estimated one in ten women of reproductive age in the UK, and while it is not caused by excess weight, the two conditions reinforce each other through insulin resistance. When cells respond poorly to insulin, the body compensates by producing more of it — and raised insulin levels stimulate the ovaries to produce extra androgens, worsening the hormonal imbalance that drives irregular periods, acne and unwanted hair growth. The NHS obesity overview explains how excess weight amplifies insulin resistance, and for women with PCOS this feedback loop can feel relentless.

This is why weight management sits at the centre of most PCOS treatment pathways. Even a 5–10% reduction in body weight has been shown in clinical studies to improve ovulation frequency, lower androgen levels and ease symptoms in overweight women with the condition. That biological reality is exactly why semaglutide comes up in conversations about PCOS: it is one of the most effective weight-management medicines available in the UK, and its mechanism (slowing gastric emptying and reducing appetite through GLP-1 receptor activation) also improves insulin sensitivity independently of weight loss, a combination we explore further on our page covering how Wegovy is used in the context of PCOS.

Worth checking before your consultation: the NHS Better Health BMI calculator takes under a minute and gives you a number that shapes your eligibility conversation with a prescriber. NHS Better Health has it on their lose-weight page.

Step 2: know what the current evidence does and does not say

The clinical evidence for semaglutide in PCOS specifically is promising but limited. The STEP 1 trial (which established semaglutide 2.4mg's weight-loss profile and was published in the New England Journal of Medicine) enrolled adults with obesity or overweight plus a weight-related condition, and women with PCOS were included in that population. Across the trial, participants lost around 15% of body weight on average over 68 weeks, with associated improvements in metabolic markers.

Smaller dedicated studies and real-world case series have reported improvements in menstrual regularity, HOMA-IR (a measure of insulin resistance) and androgen levels in women with PCOS taking GLP-1 medicines. A systematic review published in 2023 found consistent signals across these studies, though sample sizes were small and follow-up periods short. The honest position is that the weight-loss benefit is well-evidenced; the direct PCOS-specific hormonal effect is biologically plausible and supported by preliminary data, but not yet established in a large randomised trial. Researchers are actively investigating it, alongside the broader question of whether semaglutide offers meaningful cardiovascular benefits for people with metabolic conditions.

What this means practically: a prescriber can legitimately consider semaglutide for a woman with PCOS who meets the standard licensed criteria (BMI of 30 or above, or 27 or above with a weight-related condition such as insulin resistance or type 2 diabetes). They cannot prescribe it solely because a patient has PCOS, because the licence does not cover that indication. The NICE appraisal of semaglutide for weight management (NICE TA875) remains the reference point for eligibility in the UK.

Step 3: address the pregnancy and contraception question clearly

This is the part of the PCOS conversation that needs the most care. Women with PCOS are sometimes told their fertility is reduced, and while anovulation does lower the chances of conception in some cycles, it does not eliminate them. Semaglutide is not recommended during pregnancy, while breastfeeding, or when a woman is trying to conceive. The MHRA and prescribers are clear on this.

There is a further practical point: weight loss from any cause, including starting semaglutide, can restore more regular ovulation in women with PCOS who were previously not ovulating reliably. In other words, the treatment that improves metabolic health may simultaneously increase fertility, which makes contraception planning genuinely important, not a formality. Our page on Wegovy and pregnancy covers the safety picture in detail, and the dedicated page on taking Wegovy while trying to conceive addresses the timing question women ask most often.

If you are not using reliable contraception and you start semaglutide, discuss this explicitly with your prescriber at your first consultation. It is not a barrier to treatment, but it does need a plan. For women using oral contraceptives, NHS guidance recommends an additional non-oral method for the first four weeks of semaglutide treatment and after each dose increase, because gut-motility changes can temporarily affect pill absorption.

Step 4: who to talk to, and how a consultation works in practice

Semaglutide for PCOS sits at the junction of three clinical areas: weight management, reproductive endocrinology and metabolic health. Your GP is the right starting point for an overall PCOS management plan, particularly if you have not yet had a formal diagnosis or if your androgen or cycle concerns are the main issue. A specialist (gynaecologist or endocrinologist) may be appropriate if first-line management has not helped.

For weight management specifically, a prescriber at a regulated online pharmacy can assess semaglutide eligibility without a referral or a waiting list. At nume, a GPhC-registered Independent Prescriber personally reviews every consultation the same day, your answers, your medical history, your BMI, your medications. Nothing is processed by an algorithm. If semaglutide is clinically suitable, they will discuss which form fits your situation; you can explore the licensed options on our weight-loss treatments page.

Women who are already taking semaglutide for PCOS via another route and are considering switching should read how semaglutide differs between its diabetes and weight-management licences, the brand, dose and monitoring differ, and a prescriber needs to review the transfer. Our Wegovy overview sets out the full licensed weight-management picture, including the newer dose options now available in the UK.